Reviewing Cybin (OTCMKTS:CYBN) & Baudax Bio (OTCMKTS:BXRXV)

Cybin (OTCMKTS:CYBN) and Baudax Bio (OTCMKTS:BXRXV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cybin and Baudax Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	1	0	3.00
Baudax Bio	0	0	0	0	0.00

Given Baudax Bio’s higher probable upside, analysts clearly believe Baudax Bio is more favorable than Cybin.

Profitability

This table compares Cybin and Baudax Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
Baudax Bio	N/A	N/A	N/A

Institutional & Insider Ownership

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cybin and Baudax Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	$680,000.00	291.35	-$35.93 million	($6.66)	-1.49
Baudax Bio	N/A	N/A	N/A	N/A	N/A

Baudax Bio has lower revenue, but higher earnings than Cybin.

Summary

Cybin beats Baudax Bio on 5 of the 8 factors compared between the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.